Identification of ARIA regulating endothelial apoptosis and angiogenesis by modulating proteasomal degradation of cIAP-1 and cIAP-2

Endothelial apoptosis is a pivotal process for angiogenesis during embryogenesis as well as postnatal life. By using a retrovirus-mediated signal sequence trap method, we identified a previously undescribed gene, termed ARIA (apoptosis regulator through modulating IAP expression), which regulates endothelial apoptosis and angiogenesis. ARIA was expressed in blood vessels during mouse embryogenesis, as well as in endothelial cells both in vitro and in vivo. ARIA is a unique protein with no homology to previously reported conserved domain structures. Knockdown of ARIA in HUVECs by using small interfering RNA significantly reduced endothelial apoptosis without affecting either cell migration or proliferation. ARIA knockdown significantly increased inhibitor of apoptosis (cIAP)-1 and cIAP-2 protein expression, although their mRNA expression was not changed. Simultaneous knockdown of cIAP-1 and cIAP-2 abolished the antiapoptotic effect of ARIA knockdown. Using yeast 2-hybrid screening, we identified the interaction of ARIA with 20S proteasome subunit α-7. Thereafter, we found that cIAP-1 and cIAP-2 were degraded by proteasomes in endothelial cells under normal condition. Overexpression of ARIA significantly reduced cIAP-1 expression, and this reduction was abolished by proteasomal inhibition in BAECs. Also, knockdown of ARIA demonstrated an effect similar to proteasomal inhibition with respect to not only expression but also subcellular localization of cIAP-1 and cIAP-2. In vivo angiogenesis studied by Matrigel-plug assay, mouse ischemic retinopathy model, and tumor xenograft model was significantly enhanced by ARIA knockdown. Together, our data indicate that ARIA is a unique factor regulating endothelial apoptosis, as well as angiogenesis, presumably through modulating proteasomal degradation of cIAP-1 and cIAP-2 in endothelial cells.

[1]  P. Campochiaro,et al.  Dramatic inhibition of retinal and choroidal neovascularization by oral administration of a kinase inhibitor. , 1999, The American journal of pathology.

[2]  H. Verheul,et al.  Vascular endothelial growth factor and its inhibitors. , 2003, Drugs of today.

[3]  Honglin Luo,et al.  REGγ, a proteasome activator and beyond? , 2008, Cellular and Molecular Life Sciences.

[4]  R. Rousset,et al.  Effects on NF-κB1/p105 processing of the interaction between the HTLV-1 transactivator Tax and the proteasome , 1996, Nature.

[5]  L. Medeiros,et al.  Expression of inhibitor of apoptosis proteins in B‐cell non‐Hodgkin and Hodgkin lymphomas , 2006, Cancer.

[6]  M. Nakanishi,et al.  A degradation signal located in the C‐terminus of p21WAF1/CIP1 is a binding site for the C8 α‐subunit of the 20S proteasome , 2001, The EMBO journal.

[7]  T. Quertermous,et al.  Molecular Isolation and Characterization of a Soluble Isoform of Activated Leukocyte Cell Adhesion Molecule That Modulates Endothelial Cell Function* , 2004, Journal of Biological Chemistry.

[8]  R. Meller,et al.  Ubiquitin-proteasome system as a modulator of cell fate. , 2008, Current opinion in pharmacology.

[9]  T. Witte,et al.  Inhibitor of apoptosis proteins: new therapeutic targets in hematological cancer? , 2004, Leukemia.

[10]  P. Smolewski,et al.  The inhibitor of apoptosis protein family and its antagonists in acute leukemias , 2004, Apoptosis.

[11]  Z. Xiao,et al.  MDM2 promotes proteasome-dependent ubiquitin-independent degradation of retinoblastoma protein. , 2005, Molecular cell.

[12]  Yili Yang,et al.  Ubiquitin protein ligase activity of IAPs and their degradation in proteasomes in response to apoptotic stimuli. , 2000, Science.

[13]  S. Raharjo,et al.  Molecular Identification and Characterization of Novel Membrane-bound Metalloprotease, the Soluble Secreted Form of Which Hydrolyzes a Variety of Vasoactive Peptides* , 1999, The Journal of Biological Chemistry.

[14]  J. Kastrup.  Therapeutic angiogenesis in ischemic heart disease: gene or recombinant vascular growth factor protein therapy? , 2003, Current gene therapy.

[15]  K. Shimada,et al.  Therapeutic angiogenesis for patients with limb ischaemia by autologous transplantation of bone-marrow cells: a pilot study and a randomised controlled trial , 2002, The Lancet.

[16]  H. DeLisser,et al.  Platelet endothelial cell adhesion molecule (CD31). , 1993, Current topics in microbiology and immunology.

[17]  M. Dewhirst,et al.  Functional significance of Tie2 signaling in the adult vasculature. , 2004, Recent progress in hormone research.

[18]  John Calvin Reed,et al.  The c‐IAP‐1 and c‐IAP‐2 proteins are direct inhibitors of specific caspases , 1997, The EMBO journal.

[19]  Guy S. Salvesen,et al.  X-linked IAP is a direct inhibitor of cell-death proteases , 1997, Nature.

[20]  B. Ballermann,et al.  Inhibition of Capillary Morphogenesis and Associated Apoptosis by Dominant Negative Mutant Transforming Growth Factor-β Receptors (*) , 1995, The Journal of Biological Chemistry.

[21]  H. Haider,et al.  Therapeutic angiogenesis. Devising new strategies based on past experiences. , 2004, Basic research in cardiology.

[22]  M. Shibuya.  Differential roles of vascular endothelial growth factor receptor-1 and receptor-2 in angiogenesis. , 2006, Journal of biochemistry and molecular biology.

[23]  C. Print,et al.  New Insights into the Function and Regulation of Endothelial Cell Apoptosis , 2004, Angiogenesis.

[24]  J. Downward,et al.  The ubiquitin-proteasome pathway regulates survivin degradation in a cell cycle-dependent manner. , 2000, Journal of cell science.

[25]  L. Naumovski,et al.  Endothelial cell apoptosis in capillary network remodeling , 1999, Journal of cellular physiology.

[26]  P. Meier,et al.  IAP degradation: decisive blow or altruistic sacrifice? , 2002, Trends in cell biology.

[27]  David L. Vaux,et al.  IAPs, RINGs and ubiquitylation , 2005, Nature Reviews Molecular Cell Biology.

[28]  Manuel A. González,et al.  Inhibition of programmed cell death impairs in vitro vascular‐like structure formation and reduces in vivo angiogenesis , 2002, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[29]  M. Matsumura,et al.  Hypericin inhibits pathological retinal neovascularization in a mouse model of oxygen-induced retinopathy , 2008, Molecular vision.

[30]  P. Campochiaro,et al.  Blockade of vascular endothelial cell growth factor receptor signaling is sufficient to completely prevent retinal neovascularization. , 2000, The American journal of pathology.

[31]  K. Tanaka,et al.  Molecular biology of the proteasome. , 1998, Biochemical and biophysical research communications.

[32]  H. Matsubara,et al.  Glia Maturation Factor-&ggr; Is Preferentially Expressed in Microvascular Endothelial and Inflammatory Cells and Modulates Actin Cytoskeleton Reorganization , 2006, Circulation research.

[33]  I. Fidler,et al.  Apoptotic Cells Initiate Endothelial Cell Sprouting via Electrostatic Signaling , 2005, Cancer research.

[34]  S. Ylä-Herttuala,et al.  Blood Flow Remodels Growing Vasculature During Vascular Endothelial Growth Factor Gene Therapy and Determines Between Capillary Arterialization and Sprouting Angiogenesis , 2005, Circulation.